rituximab

Researchers Highlight Pediatric NMOSD Cases to Help Improve Prognosis

Most pediatric cases of neuromyelitis optica spectrum disorder (NMOSD) differed from adult cases due to antibody destruction of myelin oligodendrocyte glycoproteins (MOGs) as opposed to anti-aquaporin-4 (AQP4) autoantibodies, according to results from a study published in Multiple Sclerosis and Related Disorders. Both AQP4 and MOG antibodies necessitated the constant implementation of immunosuppressive treatments to improve…

Researchers Emphasize Clinical and Immunohematology Testing for CAD

A patient was diagnosed with cold agglutinin syndrome (CAS) after the discovery of cold-antibody autoimmune hemolytic anemia (cAIHA) and splenic marginal zone lymphoma (MZL), as published in Hematology, Transfusion and Cell Therapy. CAS was recently described as a separate but similar entity to cold agglutinin disease (CAD). “In [CAD], patients may have a B-cell clonal…

Novel TLR8 Mutation Found in Cold Agglutinin Disease

A novel toll-like receptor 8 (TLR8) gene mutation was discovered in male monozygotic twins leading to autoinflammation and severe autoimmune hemolytic anemia (AIHA) including cold agglutinin disease (CAD), as published in the American Journal of Hematology. The results showed that the TLR8 mutation led to dysregulation between TLR8 and TLR7 protein signaling. The mutation, a…

COVID-19 Associated With Hematologic Physiology in CAD

COVID-19 infection or vaccination may trigger the development of several types of cold agglutinin disease (CAD), according to results of a systematic review published in the American Journal of Clinical Pathology. These types included cold autoimmune hemolytic anemia (AIHA), warm AIHA, mixed-type AIHA, direct antiglobulin test (DAT)-negative AIHA, DAT-negative Evans syndrome, Evans syndrome, and unreported…

Rituximab Could Be First-Line Treatment for NMOSD

Researchers discovered that rituximab demonstrated sufficient efficiency and safety for the treatment of neuromyelitis optica spectrum disorder (NMOSD), as published in Therapeutic Advances in Neurological Disorders. This makes it a suitable candidate for the first-line treatment of NMOSD. Rituximab was accepted to treat NMOSD in 2005 because it therapeutically targets antibody-producing B cells and the…

Monitored COVID-19 Vaccinations Suggested for Patients With CAD

COVID-19 vaccinations are especially important for patients with complement-mediated hemolytic anemias such as cold agglutinin disease (CAD) but with meticulous monitoring for complications, according to a new study published in the journal Frontiers in Immunology. The study reports the cases of 2 patients with CAD and 2 with paroxysmal nocturnal hemoglobinuria who experienced hemolytic flares…

Autoantibody Reduction Therapy May Help Manage Acute IPF Exacerbations

Beneficial clinical responses were reported when treating acute exacerbations of idiopathic pulmonary fibrosis (IPF) with autoantibody reduction therapy, according to a recent study published in PLOS One. Patients (n=10 who survived for at least 1 year) experienced a rapid reduction in the need for supplemental oxygen flow to maintain a resting arterial oxygen saturation >92%…

Potential Biomarkers Identified for NMOSD Disease Activity and Treatment

Patients with neuromyelitis optica spectrum disorder (NMOSD) have significantly higher levels of plasma neurofilament light chain (pNfL) and plasma glial fibrillary acidic protein (pGFAP) compared to healthy controls, as found by researchers in China. These 2 proteins could serve as biomarkers for disease activity and treatment effects. “The dynamics of pNfL and pGFAP may help…

Ocular Adverse Events Associated With Multiple Sclerosis Therapies

Several therapies are associated with the development of ocular adverse events in patients with multiple sclerosis (MS), according to a report in Systematic Reviews. Colombian researchers conducted a systematic review of therapies including alemtuzumab (Lemtrada®), amantadine, fingolimod (Gilenya®), steroids, CTLA-4 Ig, estriol, interferon β, natalizumab (Tysabri®), hyperbaric oxygen, rituximab (Rituxan®), siponimod (Mayzent®), teriflunomide (Aubagio®), and…

Next post in MS News Briefs